Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Tytuł pozycji:

Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?

Tytuł :
Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?
Autorzy :
Petitpain N; Regional Pharmacovigilance Centre of Nancy, University Hospital Centre of Nancy, Nancy, France.
Devos D; Department of Medical Pharmacology, University Hospital Centre of Lille, Lille, France.; Department of Neurology, ALS Centre Lille University, Inserm UMRS_1171, LICEND COEN Centre, Lille, France.
Bagheri H; Department of Medical and Clinical Pharmacology, Regional Pharmacovigilance and Pharmacoepidemiology Centre, INSERM, UMR 1027, University Hospital Centre of Toulouse, Toulouse, France.
Rocher F; Regional Pharmacovigilance Centre of Nice, University Hospital Centre of Nice, Nice, France.
Gouraud A; Regional Pharmacovigilance Centre of Lyon, University Hospital Centre of Lyon, Lyon, France.
Masmoudi K; Regional Pharmacovigilance Centre of Amiens, University Hospital Centre of Amiens, Amiens, France.
Coquerel A; Regional Pharmacovigilance Centre of Caen, University Hospital Centre of Caen, UMR, UMR University of Caen Normandie/Inserm U1075, Caen, France.
Pokaż więcej
Źródło :
Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2019 Dec; Vol. 33 (6), pp. 689-694. Date of Electronic Publication: 2019 May 29.
Typ publikacji :
Journal Article
Język :
Journal Info :
Publisher: Blackwell Science Country of Publication: England NLM ID: 8710411 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1472-8206 (Electronic) Linking ISSN: 07673981 NLM ISO Abbreviation: Fundam Clin Pharmacol Subsets: MEDLINE
Imprint Name(s) :
Publication: <2001->: Oxford : Blackwell Science
Original Publication: Paris ; New York : Elsevier, c1987-
MeSH Terms :
Amyotrophic Lateral Sclerosis/*chemically induced
Tumor Necrosis Factor Inhibitors/*adverse effects
Adult ; Aged ; Female ; Humans ; Male ; Middle Aged ; Risk Factors
References :
Brown R.H., Al-Chalabi A. Amyotrophic lateral sclerosis. N. Engl. J. Med. (2017) 377 162-172.
Loustau V., Foltz V., Poulain C., Rozenberg S., Bruneteau G. Diagnosis of amyotrophic lateral sclerosis in a patient treated with TNFα blockers for ankylosing spondylitis: fortuitus association or new side effect of TNFα blockers? Joint Bone Spine (2009) 76 213-214.
Khalid S.I., Ampie L., Kelly R., Ladha S.S., Dardis C. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front. Neurol. (2017) 8 11.
Rothman K.J., Lanes S., Sacks S.T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. (2004) 13 519-523.
Saliba L., Moulis G., Abou Taam M. et al. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam. Clin. Pharmacol. (2016) 30 162-171.
Bougea A., Anagnostou E., Stamboulis E., Kararizou E. Amyotrophic lateral sclerosis developing during adalimumab therapy for psoriatic arthritis. Rev. Neurol. (Paris) (2014) 170 228-229.
Beers D.R., Appel S.H. Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. Lancet Neurol. (2019) 18 211-220.
Osawa Y., Banno Y., Nagaki M. et al. TNF- induced sphingosine 1-phosphate inhibits apoptosis through a phosphatidylinositol 3-kinase/Akt pathway in human hepatocytes. J. Immunol. (2001) 167 173-180.
Yin X., Ren M., Jiang H. et al. Downregulated AEG-1 together with inhibited PI3K/Akt pathway is associated with reduced viability of motor neurons in an ALS model. Mol. Cell Neurosci. (2015) 68 303-313.
Gouel F., Van Do B., Chou M.-L. et al. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways: protective effect of platelet lysate in models of neurodegenerative disease. J. Tissue Eng. Regen. Med. (2017) 11 3236-3240.
Lo S.Z., Steer J.H., Joyce D.A. Tumor necrosis factor-alpha promotes survival in methotrexate-exposed macrophages by an NF-kappaB-dependent pathway. Arthritis Res. Ther. (2011) 13 R24.
O’ Reilly E., Tirincsi A., Logue S.E., Szegezdi E. The Janus face of death receptor signaling during tumor immunoediting. Front Immunol. (2016) 7 446.
Golomb B.A., Verden A., Messner A.K., Koslik H.J., Hoffman K.B. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf. (2018) 41 403-413.
Contributed Indexing :
Keywords: TNF inhibitors; amyotrophic lateral sclerosis; pharmacovigilance
Substance Nomenclature :
0 (Tumor Necrosis Factor Inhibitors)
Entry Date(s) :
Date Created: 20190507 Date Completed: 20200413 Latest Revision: 20200413
Update Code :
Czasopismo naukowe
TNFα modulation has been reported to be either beneficial or detrimental in amyotrophic lateral sclerosis (ALS) and therefore appears as a key issue. We analysed the relationship between TNFα inhibitor (TNFi) exposure and ALS. We performed descriptive analysis of ALS reports in patients treated with TNFi, registered in the French Pharmacovigilance Database (FPvD) and disproportionality analyses by the 'case'/'non-case' method in FPvD and worldwide database (Vigibase ® ). The 8 retrieved ALS cases from the FPvD were 5 with limb-onset and 3 with bulbar-onset forms, in patients aged 43-75 years old, mainly treated for inflammatory rheumatism. The time to onset of the first symptoms ranged from 12 to 108 months, and the cumulative TNFi exposure before the diagnosis ranged from 12 to 120 months. TNFi was discontinued and thereafter survival ranged between 12 and 20 months. Disproportionality analyses showed significant associations between TNFi exposure and ALS in the FPvD and Vigibase ® (160 ALS cases), regardless comparators. A putative association between TNFi and ALS must be interpreted cautiously, but TNFi could act as a predisposing or risk factor. TNFi should therefore be avoided in patients with a known risk of ALS and discontinued in the case of neurological signs of ALS.
(© 2019 Société Française de Pharmacologie et de Thérapeutique.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies